Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C.
Andreas WeissEdwige LorthioisLouise BarysKim S BeyerClaudio BomioHeather BurksXueying ChenXiaoming CuiRuben de KanterLekshmi DharmarajanCarmine FedeleMarc GerspacherDaniel Alexander GuthyVictoria HeadAshley JaegerEloísa Jiménez NúñezJeffrey D KearnsCatherine LeblancSauveur-Michel MairaJason MurphyHelen OakmanNils OstermannJohannes OttlPascal RigollierDanielle RomanChristian SchnellRichard SedraniToshio ShimizuRowan StringerAndrea VaupelJohannes VosholPeter WesselsToni WidmerRainer WilckenKun XuFrederic ZecriAnna F FaragoSimona CotestaSaskia M BrachmannPublished in: Cancer discovery (2022)
JDQ443 is a structurally novel covalent KRASG12C inhibitor with a unique binding mode that demonstrates potent and selective antitumor activity in cell lines and in vivo models. In preclinical models and patients with KRASG12C-mutated malignancies, JDQ443 shows potent antitumor activity as monotherapy and in combination with the SHP2 inhibitor TNO155. This article is highlighted in the In This Issue feature, p. 1397.